Haemorrhagic cystitis (HC) after allogeneic haematopoietic stem cell transplantation (HSCT) or high-dose cyclophosphamide (CP) chemotherapy is a severe sideeffect and can cause significant morbidity and mortality. In this report, we describe the clinical courses of 10 patients with HC and review the literature. The patients were treated with oral conjugated estrogen in an attempt to improve severe haemorrhagic cystitis. In seven patients positive effects were seen, haematuria resolved in all, but residual symptoms of dysuria remained for longer periods. In one patient application of estrogen was interrupted because of hepatotoxicity. Two patients failed all treatment modalities including oral estrogen because of terminal illness. We conclude that in the management of HC the administration of oral conjugated estrogen should be considered. Bone Marrow Transplantation (2000) 25, 981-985.
been published. [14] [15] [16] Few have shown an encouraging effect with acceptable side-effects. Case reports about oral estrogen as an effective treatment of HC have prompted us to try this modality in affected patients. [17] [18] [19] 
Patients and methods
Ten consecutive cases of haemorrhagic cystitis after highdose chemotherapy and CP mobilisation were observed in the University Hospital of Dresden between 1 January 1997 and 31 December 1998. All patients treated with cyclophosphamide received mesna prophylaxis at a dose identical to the CP dose for 24 h with an additional bolus of 40% before the start of CP infusion. Patients were required to have a normal serum bilirubin at the time of administration of oral estrogen. Other causes of haematuria at this time were not seen. The clinical characteristics of the patients described in this report are listed in Table 1 . The severity of HC is graded according to the scale published by Bearman and colleagues. 13 
Case 1
A 27-year-old man with paroxysmal nocturnal haemoglobinuria (PNH) complained of haematuria, dysuria and polyuria 21 days after unrelated HLA-matched peripheral blood stem cell transplantation. The conditioning regime included busulfan (16 mg/kg), CP (200 mg/kg) and ATG (10 mg/kg). At the beginning, the HC was treated with hydration and analgesics (metamizole, buprenorphine). Because of persistent symptoms, oral estrogen therapy was begun at 6 mg daily and increased to 12 mg (4 mg three times a day). Bleeding resolved after 2 weeks and no further transfusion was needed. A cystoscopic washout was not required. After 4 weeks the dose could be reduced to 2 mg daily. No residual symptoms of dysuria remained. The patient is alive with persistent complete remission of the PNH.
Case 2
A 39-year-old woman with multiple myeloma (MM) developed haematuria and irritative voiding symptoms 7 days after high dose CP (4 g/m 2 ) for peripheral stem cell mobilisation. After application of 2 mg estrogen three times daily haematuria and dysuria greatly improved. Afterwards the patient received a conditioning regimen with high-dose ) followed by an autologous PBSCT without any complications.
Case 3
A 52-year-old woman developed gross haematuria with polyuria, dysuria and clots 30 days after receiving CP (120 mg/kg) and busulfan (16 mg/kg) before allogeneic related peripheral blood stem cell transplantation for multiple myeloma. Cystoscopy was required because of a transient postrenal kidney failure. During the next 8 weeks the patient was treated with 4 mg estrogen three times daily. The bleeding resolved and no further transfusion was needed. However, residual symptoms of dysuria remained for a longer period. During the next 2 months complaints have not recurred on a maintainance dose of 1 mg daily. Until now the patient lives in a stable remission of the multiple myeloma.
Case 4
A 40-year-old woman with CML received high dose CP (200 mg/kg), busulfan (16 mg/kg) and ATG (10 mg/kg). Thirty days after matched unrelated bone marrow transplantation the patient complained of haematuria, polyuria and dysuria. After application of 4 mg estrogen three times daily for 5 days the administration was interrupted because of histological proven drug induced hepatosis. The macrohaematuria continued for about 4 weeks. Residual symptoms of dysuria lasted for another month and then discontinued. The patient died from chronic GVHD on day 360 post transplant.
Case 5
A 31-year-old man with CML in blast crisis had severe HC 20 days after related two antigen mismatched peripheral blood stem cell transplantation for which he had received high-dose chemotherapy with CP (120 mg/kg), busulfan (12.4 mg/kg) and ATG (10 mg/kg). Various therapies, including continuous bladder irrigation, repeated cystoscopic bladder washouts and platelet transfusions failed to control the haemorrhage, which required between 2 and 4 units of transfused packed red blood cells daily. The patient received 4 mg estrogen three times daily, but haematuria did not disappear in the next 2 weeks until death from recurrent leukaemia.
Case 6
A 28-year-old man received total body irradiation (12 Gy), CP (120 mg/kg) and etoposide (45 mg/kg) as conditioning regime for allogeneic related peripheral blood stem transplantation for refractory relapse of ALL. Already during the high-dose chemotherapy the patient developed haemorrhagic cystitis with blood clots and urinary retention. Urine PCR testing showed polyoma BK virus to be present. Multiple cystoscopic washouts and blood transfusion were required. 6 mg estrogen daily was started on day 7 after transplantation. The patient showed initial improvement and the estrogen dose was decreased. A relapse of HC occurred 24 days later. The estrogen dose was increased to 4 mg three times daily and the patient responded again until he died from recurrent leukaemia on day 81 post transplant.
Case 7
A 38-year-old man had a severe macrohaematuria with repeated bladder tamponade. The haemorrhagic cystitis began at day 5 after CP (120 mg/kg), busulfan (10 mg/kg) and thiotepa (750 mg/m 2 ) and allogeneic unrelated bone marrow transplantation for AML. Bleeding responded transiently to continuous bladder irrigation and multiple cystoscopic washouts, diathermies and laser coagulations. Multiple units of transfused packed red blood cells were required. The clinical course was complicated by a Coombs-positive autoimmune haemolytic anaemia and postrenal kidney failure which required transient haemodialysis. Altogether the patient received 112 units of transfused packed red blood cells and more than 150 platelet transfusions. At day 70 post transplant estrogen therapy was started with 6 mg and increased to 12 mg daily (4 mg three times daily). Haematuria improved slowly 11 days later and no further transfusion and cystoscopy were needed.
Case 8
A 38-year-old man presented with gross haematuria and irritative voiding at day 4 after high-dose chemotherapy with CP (200 mg/kg), busulfan (16 mg/kg) and ATG (10 mg/kg) and allogeneic unrelated bone marrow transplantation for AML in second remission. Cystoscopic washout was required because of bladder tamponade on day 19 post transplant. Continuous bladder irrigation could not control the haematuria. At day 21 after transplantation, 12 mg estrogen daily (4 mg three times daily) were administered. Gross haematuria and dysuria improved. Estrogen was reduced after improvement at day 30 and stopped at day 51. Because of renewed macrohaematuria at day 62 the patient was treated again with estrogen 4 mg three times daily in the outpatient clinic. The dosage was tapered until day 87. The patient is alive with persistent complete haematological remission.
Case 9
A 24-year-old woman complained of polyuria and dysuria with macrohaematuria and clots 101 days after unrelated, HLA-matched peripheral blood stem cell transplantation for CML in accelerated phase. The patient had received CP (200 mg/kg), busulfan (13.2 mg/kg) and ATG (10 mg/kg) as conditioning regime. Urine PCR detected polyoma BK virus. Six days after the start of symptoms, 4 mg estrogen three times a day was initiated. Three days later clots disappeared and macrohaematuria improved, estrogen was stopped at day 14 of the administration. The patient remains in persistent remission of her disease.
Case 10
A 40-year-old man had mild HC with polyuria, dysuria and microhaematuria after receiving CP (200 mg/kg), busulfan (13.2 mg/kg) and ATG (10 mg/kg) for allogeneic, unrelated HLA-mismatched bone marrow transplantation because of CML in chronic phase. The symptoms began at day 27 post transplant. The virological examination revealed polyoma BK virus. On day 30 estrogen was initiated in a dose of 6 mg daily which was increased to 12 mg daily. Fluctuating symptoms of HC required dose adjustment. For a short time the patient needed intermittent opioids because of severe bladder spasms. On day 65 post transplant the patient was without bladder complaints and estrogen therapy was stopped. The patient is doing well and is in a persistent remission of the CML.
Results
Ten patients (four female, six male) were treated with estrogen in an attempt to improve haemorrhagic cystitis. The duration of estrogen administration varied from 5 days to 16 weeks with a median duration of 5.5 weeks. One patient received high-dose CP for stem cell mobilisation because of scheduled high-dose chemotherapy with autologous stem cell transplantation. Nine patients developed HC after allogeneic (three related, six unrelated) PBSCT/BMT (five PBSC, four BM). All patients complained of gross haematuria and irritative voiding symptoms. Four patients developed macrohaematuria without clots (mild), one patient complained of macrohaematuria with clots (moderate) and in five patients macrohaematuria with clots Bone Marrow Transplantation causing urinary tract obstruction (severe) occurred. Polyoma BK virus was implicated in three cases.
We started with 6 mg estrogen daily in three divided doses and escalated until improvement of symptoms occurred. The highest dose given was 12 mg daily. Seven of our 10 patients responded to oral estrogen. HC treated with estrogen resolved in two of four patients with mild and four of five with severe HC. Estrogen was well tolerated. Beside the hepatosis mentioned above, other side-effects like flush symptoms were not observed.
Discussion
Haemorrhagic cystitis is still an important complication after high-dose chemotherapy for HSCT and stem cell mobilisation with CP and can cause significant morbidity and mortality. The incidence of severe HC is high especially after allogeneic bone marrow transplantation. Direct urothelial toxicity seems to be most responsible for the clinical manifestation of HC, which is caused not only by cytostatic drugs but also by irradiation and virus infections like adenovirus, polyoma BK virus and cytomegalovirus. Trotman et al 7 emphasised the immunosuppression of acute GVHD as an important factor in the multifactorial pathogenesis of the HC. Thrombopenia after conditioning treatment can increase the risk of bleeding. The prevention of HC includes sufficient oral and parenteral hydration.
7-10
Hows et al 20 reported a lower incidence of cyclophosphamide-induced HC in marrow transplantation with 2-mercaptoethane sulfonate (mesna). Mesna binds to acrolein, which is responsible for urothelial toxicity as a urinary metabolite of cyclophosmamide. 21 However Trotman et al 7 described no benefit in application of mesna for prevention of HC.
Different options for treatment of HC are known. The therapy is usually initiated by intensive intravenous hydration and forced diuresis. Most patients require analgesics (sometimes even opioids) and spasmolytic drugs. In cases of severe macrohaematuria with clots bladder irrigation is a general treatment to avoid bladder tamponade. The situation may necessitate multiple blood transfusions as well. Hyperbaric oxygen offers another noninvasive therapeutic alternative in the management of radiation induced HC not responding to standard treatment. 22 The severe HC associated with urinary tract obstruction is a potentially life-threatening complication. Often invasive therapy includes cystoscopic washouts to remove blood clots. Endoscopic cauterisation of bleeding mucosal areas can be effective. Bladder instillation with formalin and other toxic substances has been reported. Further escalation of therapy involves application of a helmstein hydrostatic pressure balloon, cystotomy and cystectomy. However, these aggressive treatments cause a high incidence of hydronephrosis, bladder rupture and even death. Despite these various approaches to control HC, the therapeutic interventions are frequently of little efficacy. Case reports about estrogen as a potential treatment of HC have prompted us to try this modality in affected patients.
Potentially adverse effects of long-term exposure to estrogens include an increased risk of cancer. Metabolites of estrogens may function as initiators for preneoplastic transformation, because recent evidence in cellular and molecular oncology revealed that estrogens act by genetic and epigenetic mechanisms on cancer cells. [23] [24] [25] However, the potential carcinogenicity of high-dose estrogen administration in a short-term setting is unknown. Short-term estrogen use has been associated with other adverse effects especially hypercoagulability. 26 The potential effect of estrogen in resolving HC remains unclear, but there is some evidence that estrogen has a profound effect on the cellular and cytokine immune response during inflammation. 27 Some authors reported that estradiol enhances the healing of tissue damaged by trauma. 28, 29 It is known that estradiol promotes endothelial cell activities. 30, 31 In our group, the duration of estrogen administration varied from 5 days to 16 weeks with a median duration of 5.5 weeks. Seven of 10 patients with HC showed positive effects with resolving haematuria. However the evaluation of the efficacy is difficult, because other supportive strategies of treatment (like oral and intravenous hydration, forced diuresis, analgesics, cystoscopic washouts, diathermies and laser coagulations) were applied simultaneously in some patients.
In 1990, Liu and colleagues 18 reported five responding patients. Two patients were treated with intravenous estrogen twice daily (1 mg/kg). These patients responded within the first 8 h. Three patients received 5 mg estrogen per day orally and responded as well within 4 to 7 days. Another four patients who received only 1.25 mg daily did not profit from estrogen. Rodriguez Luna et al 19 described a single case with successful treatment in a renal transplant patient with severe idiopathic HC administrating a similar loading dose (1 mg/kg). Seven patients were treated with oral conjugated estrogen as first-line treatment of HC reported by Miller et al. 17 In six patients HC resolved. There is only one case report published by Vance 32 who pointed out a treatment failure.
In conclusion, we believe that oral estrogen is a worthwhile therapeutic option in the treatment of haemorrhagic cystitis. Our data show the feasibility and efficacy of oral estrogen. We recommend consideration of this simple and inexpensive treatment as part of the combined treatment of HC.
